亚宝药业(600351.SH)：研发项目终止临床试验并计提减值准备

Core Viewpoint - The company has decided to terminate the clinical research and development of the SY-009 project after a careful evaluation of various factors including project progress, investment risks, and future market value [1] Group 1 - The company will focus its research and development resources on more advantageous projects within its pipeline [1] - The decision to terminate SY-009 is based on a comprehensive assessment of the project's status and associated risks [1] - The company will fully recognize an impairment provision for the capitalized research and development costs of the SY-009 project in accordance with accounting prudence principles [1]